ACHV
NASDAQAchieve Life Sciences Inc.
SectorHealth CareIndustryBiotechnology: In Vitro & In Vivo Diagnostic Substances
News · 26 weeks58-40%
2026-03-012026-08-23
Mix2790d
- Insider12(44%)
- SEC Filings6(22%)
- Other5(19%)
- Analyst2(7%)
- Offering1(4%)
- Leadership1(4%)
Latest news
25 items- INSIDERDirector Stewart Richard Alistair sold $175,177 worth of shares (20,626 units at $8.49), decreasing direct ownership by 9% to 208,249 units (SEC Form 4)4 - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Issuer)
- ANALYSTMorgan Stanley initiated coverage on Achieve Life Sciences with a new price targetMorgan Stanley initiated coverage of Achieve Life Sciences with a rating of Overweight and set a new price target of $13.00
- SECSEC Form 10-Q filed by Achieve Life Sciences Inc.10-Q - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Filer)
- SECAchieve Life Sciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Filer)
- PRAchieve Life Sciences Reports Second Quarter 2026 Financial Results and Provides Business UpdatesClosed a private placement of up to $354 million, with $180 million upfront and up to $174 million from warrants exercisable prior to and up to 20 trading days following FDA approval Strengthened organization with new Chief Executive Officer, experienced commercial, CMC, and quality leaders, along with six new appointments to the Board of Directors Anticipates potential FDA approval in the first half of 2027, followed by U.S. commercial launch SEATTLE and VANCOUVER, British Columbia, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Achieve or the Company) (NASDAQ:ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of
- PRAchieve Life Sciences Appoints Ronald Dadino and Gloria Cosgrove to Lead CMC, Supply Chain, and QualitySEATTLE and VANCOUVER, British Columbia, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Achieve or the Company) (NASDAQ:ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment for nicotine dependence, today announced the appointments of Ronald Dadino as Senior Vice President, Chemistry, Manufacturing and Controls (CMC) and Supply Chain, and Gloria Cosgrove as Senior Vice President, Quality. Both executives bring decades of leadership across pharmaceutical manufacturing, supply chain, and quality. They join Achieve as the Company advances cytisinicline toward resubmission of its New Drug App
- PRAchieve Life Sciences Announced Granting of New Hire Inducement AwardsSEATTLE and VANCOUVER, British Columbia, July 31, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ:ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment for nicotine dependence, today announced that Achieve’s board of directors approved stock option grants to purchase an aggregate of 1,190,000 shares of its common stock and restricted stock unit ("RSU") awards covering an aggregate of 125,000 shares of its common stock for six new employees under Achieve’s 2024 Equity Inducement Plan. The stock options have an exercise price equal to the closing price of Achieve’s common stock on the grant d
- INSIDERSEC Form 4 filed by Director Sellig Thomas4 - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Issuer)
- INSIDERSEC Form 4 filed by Director Martin Christopher Nathan4 - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Issuer)
- INSIDERSEC Form 4 filed by Director Royston Aaron4 - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Issuer)
- INSIDERSEC Form 4 filed by Director Waldman Reid Alexander4 - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Issuer)
- INSIDERSEC Form 4 filed by Director Stewart Richard Alistair4 - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Issuer)
- INSIDERSEC Form 4 filed by Director Farrow Jeffrey S4 - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Issuer)
- INSIDERSEC Form 4 filed by Director Phelan Nancy R.4 - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Achieve Life Sciences Inc.SCHEDULE 13G/A - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Subject)
- SECAchieve Life Sciences Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Filer)
- PRAchieve Life Sciences Joins Russell 2000® IndexSEATTLE and VANCOUVER, British Columbia, June 29, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Achieve or the Company) (NASDAQ:ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment for nicotine dependence, today announced that it has been added to the Russell 2000® Index, effective June 26, 2026, as part of the Russell U.S. Indexes reconstitution. The Company is also a member of the Russell 3000® Index. Approximately $12.2 trillion in assets, as of June 30, 2025, are benchmarked against the Russell U.S. Indexes, making them one of the most widely used benchmarks for institutional investors, ind
- ANALYSTRaymond James resumed coverage on Achieve Life Sciences with a new price targetRaymond James resumed coverage of Achieve Life Sciences with a rating of Strong Buy and set a new price target of $20.00
- PRAchieve Life Sciences Receives Complete Response Letter from FDA for Cytisinicline NDACRL Cites Deficiencies at Third-Party Manufacturing Facility No Efficacy or Clinical Safety Deficiencies Identified SEATTLE and VANCOUVER, British Columbia, June 22, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Achieve or the Company) (NASDAQ:ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence, today announced that it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the New Drug Application (NDA) for cytisinicline. The CRL relates to outstanding manufacturing-related observations from a current Good Manufacturing
- SECSEC Form DEF 14A filed by Achieve Life Sciences Inc.DEF 14A - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Filer)
- INSIDERSEC Form 4 filed by Director Waldman Reid Alexander4 - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Issuer)
- INSIDERSEC Form 4 filed by Director Farrow Jeffrey S4 - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Issuer)
- INSIDERNew insider Waldman Reid Alexander claimed no ownership of stock in the company (SEC Form 3)3 - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Issuer)
- INSIDERNew insider Farrow Jeffrey S claimed no ownership of stock in the company (SEC Form 3)3 - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Issuer)
- SECAchieve Life Sciences Inc. filed SEC Form 8-K: Leadership Update8-K - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Filer)
ACHV FAQ
6 questionsWhat does Achieve Life Sciences Inc. do?
Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes of cytisinicline for smoking cessation and nicotine addiction in the United States and internationally. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain to help reduce the severity of nicotine withdrawal symptoms. It has license agreements with Sopharma AD and University of Bristol. The company is based in Vancouver, Canada.Where does ACHV stock trade?
Achieve Life Sciences Inc. (ACHV) is listed on NASDAQ.What sector and industry is ACHV in?
Achieve Life Sciences Inc. operates in the Health Care sector, Biotechnology: In Vitro & In Vivo Diagnostic Substances industry.What are analysts saying about ACHV?
Achieve Life Sciences Inc. has had 8 recent analyst actions on file. The most recent action was from Morgan Stanley: Overweight with a $1300.00 price target on 2026-08-13. Recent price targets range from $1200.00 to $2000.00.What companies are similar to ACHV?
Notable peers in the same industry include IDXX (IDEXX Laboratories Inc.), ORKA (Oruka Therapeutics Inc.), LNTH (Lantheus Holdings Inc.), OCDX (Ortho Clinical Diagnostics Holdings plc), CLDX (Celldex Therapeutics Inc.). Compare ACHV side-by-side with any of them on Quantisnow.How can I track ACHV on Quantisnow?
Quantisnow aggregates Achieve Life Sciences Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ACHV to receive live email and push alerts on every new disclosure.